Illustration: Shutterstock
December 8, 2023 07:16 AM ESTUpdated 08:40 AM
Bioregnum

The End­points 100 sur­vey: Has biotech hit rock bot­tom?

John Carroll

Editor & Founder

There may be a sol­id chunk of ex­ec­u­tives in the End­points 100 who feel that bet­ter times are ahead for the biotech in­dus­try in 2024 …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times